2nd Quarter - Report

SEQIRUS for SEQIRUS

Firm
Client
Income
—
Expenses
$110,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Pandemic All-Hazards Preparedness Act Reauthorization; federal appropriations for preparedness, biodefense, and influenza; regulatory issues related to biodefense and influenza preparedness.

Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.

LobbyistCovered position, as disclosed
PHYLLIS FROSST —

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.